Breast Implant Illness (BII)

Breast Implant Illness refers to a cluster of systemic symptoms some patients experience after breast implant placement. The medical community continues to investigate. Your symptoms — whatever their cause — deserve careful evaluation and an honest conversation about whether explant may help.

Breast Implant Illness (BII) describes a constellation of systemic symptoms — fatigue, brain fog, joint pain, autoimmune-like features — that some women experience after breast implant placement and which often improve after implant removal. The FDA acknowledges BII and has updated implant labeling accordingly, though the precise biological mechanism remains under research.

What is BII?

"Breast Implant Illness" is a term used to describe a syndrome of systemic symptoms some patients report after breast augmentation or reconstruction. The term originated in patient communities and has been increasingly used by surgical societies as patient advocacy has grown.

BII is not a single disease with a defined mechanism, biomarker, or diagnostic test. It is a patient-reported symptom cluster. The FDA's 2019 advisory committee acknowledged that "some patients with breast implants experience adverse health effects" while noting that the mechanism is not fully understood and that studies are limited by methodological challenges.

Commonly reported symptoms

Patients who identify with BII typically report multiple symptoms from across several body systems. The most commonly reported include:

Current medical evidence

What we know

• A subset of breast implant patients report systemic symptoms that often improve after explant
• The FDA, ASPS, and ISAPS acknowledge BII as a real patient experience worth investigating
• The FDA added boxed warnings to all breast implants in 2021, requiring patient checklists discussing systemic symptom risk
• Several patient-reported outcome studies show symptom improvement following explant in 50-80% of patients

What is uncertain

• The biological mechanism (if any) by which implants cause systemic symptoms
• Why some patients are affected and others are not
• Whether there are specific implant types or surgical techniques that increase risk
• Whether symptom improvement after explant is due to physical removal, placebo effect, regression to the mean, or some combination
• What proportion of "BII symptoms" would have occurred regardless of implants

What is not supported

• Specific autoimmune diseases (lupus, MS, RA) being caused by implants — large epidemiological studies have not confirmed this
• Claims that any specific implant brand is "safe" or "toxic" beyond the established BIA-ALCL textured implant concerns
• The idea that en-bloc capsulectomy is medically necessary for BII (vs. total capsulectomy, which is equivalent)

Before considering explant for BII

A thorough workup with your primary physician is recommended to:

1. Rule out other causes for your symptoms — thyroid disorders, anemia, vitamin D deficiency, B12 deficiency, sleep apnea, autoimmune disease, mood disorders
2. Document your symptoms with timestamps and severity scores — this helps measure change after explant
3. Get current breast imaging (MRI is gold standard) to identify silent rupture or other implant problems
4. Check implant records if available — manufacturer, model, year, surface texture, volume
5. Consider mental health support — chronic symptoms of any cause benefit from psychological support during evaluation and recovery

This is not to suggest your symptoms are psychological — it is the same workup any patient with multi-system symptoms deserves before major surgery.

The surgical approach for BII patients

For patients seeking explant due to BII concerns, the surgical goal is complete capsule removal. This can be achieved by:

• Total capsulectomy: All capsule tissue removed; pieces removed in sections as anatomically required. Medically equivalent for BII.
• En-bloc capsulectomy: Implant + capsule removed as single unit. Indicated specifically for BIA-ALCL or ruptured silicone; offered when surgically feasible for patients with strong preference.

Both approaches achieve the goal of removing all implant-related tissue. We do not promote en-bloc as superior to total capsulectomy for BII — this is not supported by current evidence.

What improvement may look like

Patient-reported improvement after explant varies widely. Some general patterns from published studies:

• Early improvement (weeks 1-4): Some patients report improved sleep, reduced chest pressure, easier breathing
• Medium-term (months 1-6): Fatigue, brain fog, and joint pain are commonly reported as improving
• Long-term (months 6-12): Skin, hair, and constitutional symptoms continue to evolve; final symptom assessment recommended at 12 months
• Non-responders: 20-50% of patients in published studies report no significant change or partial improvement only

Predictors of response are not well established. Younger patients, shorter implant duration, and absence of confirmed autoimmune disease may predict better outcomes — but this is hypothesis, not proven.

BII FAQ